Breaking News, Financial News

Gilead 4Q Results

Product sales were down due to lower Veklury and HIV sales, partially offset by higher Oncology sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead 4Q Revenues: $7.1 billion (-4%) 4Q Earnings: $1.4 billion (-13%) FY Revenues: $27.1 billion (-1%) FY Earnings: $5.6 billion (+23%) Comments: Product sales were down in the quarter due to lower Veklury (remdesivir) and HIV sales, partially offset by higher Oncology sales. Veklury sales were down 28% to $720 million. Descovy sales were down 5% to $509 million in the quarter. Biktarvy sales were up 7% in the quarter to $3.1 billion. Liver Disease portfolio sales were flat at $691 millio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters